Actavia Life Sciences, Inc. (RASP)

Market Cap	385.91K -87.5%
Revenue (ttm)	n/a
Net Income	-406.65K
EPS	-0.00
Shares Out	771.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Open	0.0005
Previous Close	0.0100
Day's Range	0.0005 - 0.0005
52-Week Range	0.000001 - 0.0100
Beta	-81.78
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Actavia Life Sciences

Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301. The company was formerly known as Rasna Therapeutics, Inc. and changed its name to Actavia Life Sciences, Inc. in October 2023. Actav...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: RASP

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 19, 2026

Data Sources Report a data error